Company news
Cascade Copper Corp. news in 2009
Cascade Copper Corp.'s news releases, calls and decks from 2009, newest first.
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in Asian patients with NSCLC
December 10, 2009
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
November 16, 2009
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
November 11, 2009
Smurfit-Stone nomme Michael Exner à titre de vice-président directeur et directeur général de la division de la fabrique de cartons-caisses
November 5, 2009
Smurfit-Stone Appoints Michael Exner Senior Vice President and General Manager, Containerboard Mill Division
November 5, 2009
Oncothyreon announces webcast of third quarter 2009 financial results conference call
November 2, 2009
Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
October 5, 2009
Oncothyreon to present at BioCentury NewsMakers Conference
September 10, 2009
Oncothyreon to present at Rodman & Renshaw Global Healthcare Conference
September 3, 2009
Oncothyreon reports second quarter 2009 financial results
August 12, 2009
Oncothyreon announces closing of $15.0 million registered direct financing
August 10, 2009
Oncothyreon announces webcast of second quarter 2009 financial results conference call
August 6, 2009
Oncothyreon announces commitments to purchase $15.0 million of company securities in a registered direct financing
August 4, 2009
Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
August 4, 2009
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
August 3, 2009
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
June 22, 2009
Oncothyreon appoints Scott Peterson as Vice President of Research and Development
June 15, 2009
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
May 30, 2009
Oncothyreon announces closing of $11.1 million registered direct financing
May 27, 2009
Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
May 20, 2009
Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis
May 18, 2009
Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2009
Oncothyreon reports first quarter 2009 financial results
May 14, 2009
Oncothyreon regains compliance with NASDAQ listing requirements
March 16, 2009
Oncothyreon to present at Invest Northwest 2009
March 13, 2009
Oncothyreon reports full year and fourth quarter 2008 financial results
March 9, 2009
Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
March 3, 2009
Oncothyreon to present at BIO CEO & Investor Conference 2009
February 3, 2009